Replies to post #531309 on $Stock*Shop*Charts*News*Option$

[Tuff-Stuff]

AZN $65.00>European regulators have approved AstraZeneca's (AZN) Xigduo treatment for Type 2 diabetes.
The authorization is the first for a drug that combines an SGLT2 inhibitor, which cuts the reabsorption of excess glucose, and metformin, a standard therapy